20.06.2014 • News

Recipharm and CTC in Clinical Trial Collaboration

CTC Clinical Trial Consultants of Uppsala, Sweden, and compatriot Recipharm Pharmaceutical Development of Solna, Stockholm, Sweden, have begun a collaboration to offer a complete set of packages for Phase I studies including development and manufacture of clinical trial material.

The scope of the cooperation will extend to planning, performing and evaluation of the clinical trial.

Maria Lundberg, general manager Recipharm Pharmaceutical Development, said the link-up will allow the two companies to offer customers faster and more cost-efficient phase I studies. "We can from now on take full responsibility for coordination of the work which might be valuable to small virtual companies."

CTC has "excellent experience" in clinical trials and a unique phase I unit at Uppsala University Hospital (Akademiska Sjukhuset), Lundberg noted.

Beyond shortening project timelines, Bengt Dahlström, CEO of CTC Clinical Trial said the systematic integrated approach will help the companies to obtain more information on the desirable properties of the drug formulation.

"Adaptive design," he said, "is a key element in getting more information from each study and modifying the design based on the data obtained all within a single protocol."

Interview

The UK Chemical Supply Chain
Trade and Competitiveness

The UK Chemical Supply Chain

The CBA, led by CEO Tim Doggett, is steering the UK chemical supply chain through trade uncertainty, sustainability pressures and logistics challenges, as he explains in this interview with CHEManager.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.